Quarter
Charts

Denali Therapeutics Inc. — Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Working Capital Analysis

Valuation Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-3
Book Value Per Share
$6
Free Cash Flow Per Share
$-2
Cash Per Share
$1
Revenue Per Share
$0
OCF Per Share
$-2
Return on Equity
-45.7%
Return on Assets
-40.7%
Return on Invested Capital
-39.1%
Current Ratio
9.16
Quick Ratio
9.16
Asset Turnover
0.00
Days Sales Outstanding
—
R&D / Revenue
—
SBC / Revenue
—
Capex / Revenue
—
Working Capital
$802M
Net Current Asset Value
$770M
Invested Capital
$1.01B
OCF / Net Income
0.81
FCF / Net Income
0.82
Accruals Ratio (Sloan)
-8.7%
Net Debt
$-868M
Net Debt / EBITDA
1.59
Capex Coverage
-43.42
Tangible Common Equity
$1.01B
TCE / Total Assets
88.5%
NOPAT
$-439M
Cash ROIC
-37.6%
WC / Revenue
—
Capex / D&A
0.85
Reinvestment Rate
0.3%
Asset Growth vs Revenue Growth
119.1%
Revenue 5Y CAGR
—
Book Value 5Y CAGR
-2.5%
Stock Price (FY-end)
$17
Market Cap
$2.85B
P/E Ratio
—
P/S Ratio
—
P/B Ratio
2.81
P/TB Ratio
2.81
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
$1.98B
EV / EBITDA
—
EV / Sales
—
EV / FCF
—
FCF Yield
-14.8%
Shareholder Yield
-3.5%
R&D Yield
14.7%
Capex Yield
0.3%
Graham Number
—
Shares Variation (YoY)
5.0%
Beta (5Y)
1.59
Cost of Equity
12.5%
52W High
$24
52W Low
$11
Trailing Return 1Y
-19.9%
Trailing Return 5Y
-81.3%
F-Score (Piotroski)
2.00
Z-Score (Altman)
9.78

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

Denali Therapeutics Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes———0.00%0.00%-0.30%
Foreign Rate Differential———0.00%0.00%0.00%
Other Adjustments0.10%0.10%-0.40%-2.30%0.00%0.20%
R&D Tax Credits9.20%-4.10%-4.90%-15.90%-5.90%-4.30%
SBC (Nondeductible)———-4.00%-2.30%-1.20%
Valuation Allowance Change-4.00%-28.20%-25.10%-26.10%-25.30%-24.20%
Tax Law Change1.10%0.00%0.00%0.00%0.00%0.00%
Effective Tax Rate1.10%0.20%-0.10%0.00%0.00%0.00%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$823.0K−$575.0K$21.0K$30.0K$68.0K$102.0K
Income Taxes Paid (Cash)—$210.0K$47.0K$3.0K—$46.0K